title: Therapy: Immunogenicity of biologic therapies-we need tolerance.
authors.forename: Charlotte L M
authors.initials: CL
authors.lastname: Krieckaert
authors.forename: G Margret
authors.initials: GM
authors.lastname: Bartelds
authors.forename: Gerrit-Jan
authors.initials: GJ
authors.lastname: Wolbink
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D051379:Mice; D011485:Protein Binding / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab